Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti‐angiogenesis activity in a preclinical cancer model

MLA

Satoshi Kawano, et al. “Multitargeting Strategy Using Lenvatinib and Golvatinib: Maximizing Anti‐angiogenesis Activity in a Preclinical Cancer Model.” Cancer Science, vol. 106, Feb. 2015, pp. 201–07. EBSCOhost, https://doi.org/10.1111/cas.12581.

APA

Satoshi Kawano, Takayuki Nakagawa, Tomohiro Matsushima, Junji Matsui, Osamu Tohyama, Hiroki Muto, Youya Nakazawa, & Yasuhiro Funahashi. (2015). Multitargeting strategy using lenvatinib and golvatinib: Maximizing anti‐angiogenesis activity in a preclinical cancer model. Cancer Science, 106, 201–207. https://doi.org/10.1111/cas.12581

Chicago

Satoshi Kawano, Takayuki Nakagawa, Tomohiro Matsushima, Junji Matsui, Osamu Tohyama, Hiroki Muto, Youya Nakazawa, and Yasuhiro Funahashi. 2015. “Multitargeting Strategy Using Lenvatinib and Golvatinib: Maximizing Anti‐angiogenesis Activity in a Preclinical Cancer Model.” Cancer Science 106 (February): 201–7. doi:10.1111/cas.12581.